Les Meilleures Cliniques et Coûts des traitements de neuroblastome en Grèce 2026

Pediatric neuroblastoma is primarily treated in specialized oncology units in Athens and Thessaloniki. The Marianna Vardinoyannis ELPIDA Children's Oncology Unit is the leading center. It treats 30% of Greek pediatric cancer cases and offers autologous stem cell rescues in dedicated units.

• Specialized units: Athens hosts the Agia Sophia and P. and A. Kyriakou hospitals.
• Thessaloniki centers: Ippokratio and AHEPA University Hospitals provide multidisciplinary care for Northern Greece.
• Treatment protocols: Greek medical teams strictly follow Society of Pediatric Oncology Europe Neuroblastoma protocols.
• Multidisciplinary care: Treatment involves coordinated teams of pediatric surgeons, radiologists, and ICU specialists.

Bookimed Expert Insight: While local centers like Veselibu Clinic in Thessaloniki meet international standards for rehabilitation, acute neuroblastoma care is concentrated in large university hubs. Our data shows that complex cases naturally flow to Athens. Most top-tier public facilities there serve over 2,000 patients yearly. This high volume ensures teams stay proficient in rare embryonal tumor protocols.

Patient Consensus: Patients note it is vital to keep all care in one specialized center. They emphasize asking about the team's specific case volume for rare tumors like neuroblastoma. Most families recommend getting a second opinion on pathology and staging before starting treatment.

Greek hospitals strictly follow internationally recognized neuroblastoma protocols established by the International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN). Pediatric oncology units utilize the International Neuroblastoma Risk Group Staging System (INRGSS) to standardize diagnosis. Treatment pathways align with pan-European clinical research frameworks for consistency.

• Staging standards: Greek specialists use INSS and INRGSS for accurate cancer risk classification.
• Clinical trials: Centers participate in the SIOPEN HR-2 trial for high-risk neuroblastoma patients.
• Biological markers: Hospitals routinely screen for MYCN gene amplification to determine treatment intensity.
• Multimodal approach: Protocols include rCOJEC induction chemotherapy, stem cell rescue, and Dinutuximab beta immunotherapy.

Bookimed Expert Insight: Greek pediatric oncology centers like those in Thessaloniki serve approximately 2,000 patients annually. While smaller than some European hubs, their government-certified facilities for international patients guarantee compliance with EU-wide standards. This ensures high-risk protocols like the MONALISA project trials are accessible without traveling to Western Europe.

Patient Consensus: Families emphasize that protocol consistency is more important than hospital reputation alone. They recommend confirming if local teams coordinate with international groups for high-risk case management.

Greek centers follow SIOPEN protocols developed by the Society of Pediatric Oncology Europe Neuroblastoma. Plans are strictly risk-adapted based on tumor biology and age. High-risk cases use the Rapid COJEC chemotherapy regimen. This intensive cycle delivers eight treatments every ten days to target metastases aggressively.

• Low-risk protocols: Observation or surgical resection is often sufficient for localized tumors in infants.
• Intermediate-risk care: Moderate chemotherapy cycles are used alongside surgery to manage non-aggressive genetic markers.
• High-risk induction: Rapid COJEC cycles alternate cisplatin and vincristine to clear circulating tumor cells.
• Consolidation phase: Patients receive high-dose chemotherapy followed by autologous stem cell rescue for immunity.
• Maintenance therapy: Dinutuximab beta immunotherapy and isotretinoin are used to prevent cancer from returning.

Bookimed Expert Insight: Greek pediatric oncology centers coordinate multi-phase care across specialized departments. For example, Thessaloniki facilities like Veselibu Clinic manage high patient volumes and maintain infrastructure for complex recovery. While some centers focus on the primary surgery, high-risk protocols require a facility with integrated pediatric ICU and stem cell capabilities.

Patient Consensus: Patients note that tumor biology markers often change the treatment plan more than tumor location does. They emphasize that surgery is usually safer after chemotherapy cycles have effectively shrunk the initial mass.

Anti-GD2 immunotherapy is available in Greece at specialized pediatric oncology centers for high-risk neuroblastoma. These monoclonal antibodies require intensive monitoring for neuropathic pain. Access usually depends on protocol eligibility. Tertiary centers in Athens and Thessaloniki coordinate these complex treatments.

• Approved therapies: Dinutuximab and Naxitamab are standard monoclonal antibodies for high-risk cases.
• Center types: Therapy occurs in specialized hospitals equipped for heavy supportive care.
• Pain management: Facilities must provide dedicated protocols to manage infusion-related neuropathic pain.
• Eligibility criteria: Treatment is typically reserved for high-risk, relapsed, or refractory neuroblastoma.

Bookimed Expert Insight: Greek patients often find that smaller regional clinics lack the infrastructure for anti-GD2 monitoring. Veselibu Clinic in Thessaloniki maintains government certification for international standards. However, neuroblastoma cases frequently require transfer to larger academic hospitals. Confirm if your center has a dedicated pain-control protocol before starting.

Patient Consensus: Patients emphasize that anti-GD2 is a physically demanding treatment involving fever and pain. It is vital to ask your oncologist early if this therapy is included in your child's specific risk-group plan.

Full autologous stem-cell transplants are performed in Greece. These procedures follow European Union standards for oncology. Facilities like Agia Sofia Children hospital provide specialized pediatric care. Treatments often combine high-dose chemotherapy with stem-cell rescue. Greek centers must adhere to strict regulatory protocols.

• Procedure scope: Includes cell harvesting, high-dose chemotherapy, and re-infusion stages.
• Pediatric expertise: Specialized units manage high-risk neuroblastoma protocols for children.
• Facility requirements: Clinical standards mandate isolation rooms and pediatric ICU backup.
• Regulatory compliance: Centers operate under national and European healthcare quality regulations.

Bookimed Expert Insight: While Greece maintains specialized centers like Veselibu Clinic, which serves 2,000 patients annually, pediatric neuroblastoma cases require highly specific equipment. Success often depends on on-site stem-cell cryogenic storage and rapid fever response teams. Patients should verify if a facility handles the entire sequence from induction to consolidation.

Patient Consensus: Parents emphasize that center selection matters more than the transplant technique itself. They note it is vital to check if the hospital team handles pediatric complications daily.

Relapsed or refractory neuroblastoma is treated with multimodal strategies to induce a second remission. Primary options include re-induction chemotherapy, targeted radiation like iodine-131-MIBG therapy, and immunotherapy. Greece offers advanced pediatric oncology services, including specialized CAR NK cell therapy and complex multidisciplinary care at accredited facilities.

• Re-induction chemotherapy: Doctors use drug combinations different from frontline therapy to overcome resistance.
• I-131 MIBG therapy: Targeted radioactive molecules deliver concentrated radiation directly to neuroblastoma tumor cells.
• Immunotherapy: Anti-GD2 monoclonal antibodies like naxitamab help the immune system identify cancer.
• Molecular profiling: Genetic testing identifies actionable mutations like ALK for personalized targeted therapies.

Bookimed Expert Insight: While many families seek centers in Turkey or Spain due to high volumes, Greece provides a vital gateway for advanced cellular therapies like CAR NK cell therapy. Facilities like Veselibu Clinic in Thessaloniki manage 2,000+ patients annually. This indicates strong local capacity for complex pediatric supportive care during intensive salvage regimens.

Patient Consensus: Patients note it is important to focus on trial eligibility after a relapse. Families emphasize getting a molecular biopsy to find the next practical treatment option.